Clinical Trials Browser

Select Advanced Solid Tumors × pembrolizumab × Clear all

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors